Method for evaluating onset risk of non-alcoholic fatty liver disease, and biomarkers
The method of detecting specific compounds in body fluids using mass spectrometry provides a reliable prediction of NAFLD risk, addressing the limitations of existing methods by considering multiple factors and achieving high predictive accuracy for NAFLD development.
Patent Information
- Application Number
- PCT/JP2024/017846
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for predicting the risk of non-alcoholic fatty liver disease (NAFLD) are unreliable due to their limited sample sizes and failure to consider both genetic and environmental factors, necessitating a more robust and comprehensive approach for early detection and prevention.
A method involving the detection of 14 specific compounds (lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan) in body fluids using mass spectrometry, with predictive discriminant formulas to assess the risk of NAFLD development, allowing for high reliability in predicting future disease onset.
This approach enables accurate and reliable prediction of NAFLD risk, as demonstrated by high Area Under the Curve (AUC) values in ROC analysis, facilitating early intervention and preventive measures.
Smart Images

Figure JP2024017846_21112024_PF_FP_ABST
Abstract
Description
Method for assessing risk of developing non-alcoholic fatty liver disease and biomarkers
[0001] The present invention relates to a method for assessing the risk of developing non-alcoholic fatty liver disease and a biomarker used therein.
[0002] Nonalcoholic fatty liver disease (NAFLD) is a general term for fatty liver not caused by alcohol or viruses. NAFLD includes simple fatty liver, in which fat is simply deposited in hepatocytes, and nonalcoholic steatohepatitis (NASH), in which hepatocytes are destroyed and no longer function, leading to inflammation and fibrosis from fatty liver and the risk of progression to cirrhosis or liver cancer. Because simple fatty liver can lead to nonalcoholic steatohepatitis, diagnosing NAFLD, including NASH and simple fatty liver, is important. In addition to diagnosing whether a patient currently has NAFLD, diagnosing the patient's risk of developing NAFLD in the future is also meaningful because it allows for recommendations for preventive measures against NAFLD.
[0003] As methods for predicting the risk of developing such a disease, for example, a prediction method for measuring the total amount of acylcarnitines in a sample (Patent Document 1), a prediction or isolation method for measuring the concentration of growth differentiation factor 15 protein in a sample (Patent Document 2), a method for comparing the levels of trimethylamine-containing compounds (Patent Document 3), etc. have been proposed. However, these methods are only applicable to analyses on a scale of 200 people at most, and are insufficient in terms of reliability.
[0004] On the other hand, a method for predicting NAFLD risk has been proposed that analyzes thousands of people by detecting a single nucleotide polymorphism at position 27730940 of the GCKR gene on human chromosome 2, or a single nucleotide polymorphism in linkage disequilibrium with the single nucleotide polymorphism (Patent Document 4).
[0005] Japanese Patent Application Laid-Open No. 2020-34561 Japanese Patent Application Laid-Open No. 2020-528138 Japanese Patent Application Laid-Open No. 2012-528340 Japanese Patent Application Laid-Open No. 2020-120625
[0006] However, the method described in Patent Document 4 employs a genetic analysis method using primers and probes that hybridize to specific base sequences (SNPs), and therefore predicts onset based on genetic background (constitution) and does not take into account internal or external environmental factors. Therefore, alternative methods other than genetic analysis are desired.
[0007] Therefore, an object of the present invention is to provide a highly reliable method for assessing the risk of developing NAFLD and a biomarker to be used therefor.
[0008] A method for assessing the risk of developing non-alcoholic fatty liver disease according to a first aspect of the present invention comprises an obtaining step of obtaining a sample derived from the body fluid of a subject; a detecting step of detecting 14 types of compounds in the sample, including lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan; and an using step of using all of the detected amounts of the 14 types obtained in the detecting step.
[0009] According to the method for assessing the risk of developing a non-alcoholic fatty liver disease and the biomarker of the first aspect of the present invention, it is possible to predict with high reliability whether or not a person will develop a non-alcoholic fatty liver disease in the future.
[0010] FIG. 1 is a graph showing the performance of the prediction discriminant in Example 1 (31 types of specific compounds) evaluated by an ROC curve; in the right figure, the sample cohort is the training set, and in the right figure, the sample cohort is the test set. In FIG. 1, the vertical axis represents sensitivity, and the horizontal axis represents non-specificity (1-specificity). FIG. 2 is a graph showing the performance of the prediction discriminant in this Example evaluated by an ROC curve for a cohort different from that in FIG. 1. FIG. 3 is a graph showing the performance of the prediction discriminant in Example 2 (21 types of specific compounds) evaluated by an ROC curve; in the right figure, the sample cohort is the training set, and in the right figure, the sample cohort is the test set. FIG. 4 is a graph showing the performance of the prediction discriminant in Example 3 (15 types of specific compounds) evaluated by an ROC curve; in the right figure, the sample cohort is the training set, and in the right figure, the sample cohort is the test set. FIG. 5 is a graph showing the performance of the prediction discriminant in Example 4 (14 types of specific compounds) evaluated using an ROC curve, in which the sample cohort is the training set in the right panel and the sample cohort is the test set in the left panel.
[0011] 1. First Embodiment A risk assessment method according to a first embodiment of the present invention is a method for assessing the presence or absence of future onset of non-alcoholic fatty liver disease (hereinafter sometimes abbreviated as "NAFLD"), and uses 14 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan as biomarkers for assessing the risk of developing NAFLD. Specifically, the assessment method according to the first embodiment comprises an obtaining step, a detecting step, and a using step. Each step is described in detail below.
[0012] (Obtaining Step) In this step, a sample derived from the body fluid of a subject is obtained.
[0013] Examples of body fluids include blood, urine, saliva, sweat, sputum, and feces. Examples of blood include whole blood, plasma, and serum. Preferably, blood is used, and more preferably serum. Blood is minimally invasive, is a target sample for screening in health checkups, and is easily available.
[0014] The sample is temporarily stored before the detection step. The storage method may be frozen, refrigerated, or stored at room temperature. When serum or plasma is used as the sample, it may be stored in the form of whole blood, or in the form of serum or plasma obtained by centrifuging whole blood.
[0015] (Detection Step) In this step, at least all of the 14 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan are detected from the sample. Hereinafter, these 14 types of compounds are also collectively referred to as specific compounds.
[0016] In this embodiment, "detecting a compound" refers to directly or indirectly detecting a specific compound contained in a sample for quantification, and specifically includes not only detecting the specific compound itself, but also performing processing such as ionization, dissociation, or derivatization on the specific compound, and detecting the processed specific compound (ionized product, dissociated product, derivative, etc.).
[0017] The detection method may be any method capable of quantifying a specific compound contained in a sample, and examples thereof include gas chromatography (GC), liquid chromatography (LC), mass spectrometry (MS), gas chromatography / mass spectrometry (GC / MS), liquid chromatography / mass spectrometry (LC / MS), nuclear magnetic resonance spectroscopy, immunological detection methods, etc. From the viewpoint of enabling highly sensitive detection of blood samples, preferred are methods using mass spectrometry (MS, LC / MS, GC / MS), and more preferred are GC / MS.
[0018] When mass spectrometry is employed, examples of ionization methods include electron ionization (EI), electrospray ionization (ESI), and atmospheric pressure chemical ionization (APCI). Examples of mass separation methods include quadrupole, magnetic sector, time-of-flight, ion trap, and ion cyclotron resonance. Other examples include tandem mass separation methods such as triple quadrupole (Q-Q), tandem time-of-flight (TOF-TOF), quadrupole-time-of-flight (Q-TOF), quadrupole-ion trap (Q-IT), quadrupole-ion cyclotron resonance (Q-ICR), and ion trap-time-of-flight (IT-TOF).
[0019] Before carrying out the detection step, the sample may be subjected to pretreatment. Examples of pretreatment include treatments for the purpose of purification, derivatization, etc. For example, when detecting serum or the like by mass spectrometry, it is preferable to carry out deproteinization treatment, derivatization, etc.
[0020] The deproteinization treatment is carried out, for example, by mixing an extraction solvent such as chloroform solvent, water, or the like with the sample, centrifuging the mixture, and removing the precipitate from the mixture after centrifugation.
[0021] Examples of derivatization include silylation such as trimethylsilylation, dimethylsilylation, and halomethylsilylation; esterification such as methyl esterification; acylation; and alkylation. From the viewpoints of the large number of target compounds that can be derivatized, the ability to react with many compounds having active hydrogen, and the ability to give peaks that facilitate analysis in mass spectra, silylation is preferred, and trimethylsilylation is particularly preferred. That is, it is preferred to use the detected amount of a derivative of a specific compound, particularly a trimethylsilylated derivative of a specific compound.
[0022] When trimethylsilylation is employed, for example, a methoxyamine solution is added to a freeze-dried sample to convert it into an oxime, followed by the addition of a trimethylsilylating agent such as N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) or N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA).
[0023] Examples of trimethylsilylated derivatives of specific compounds include bis(trimethylsilyl)lactic acid (Lactic acid-2TMS), bis(trimethylsilyl)alanine (Alanine-2TMS), trimethylsilylacetylglycine (Acetylglycine-TMS), bis(trimethylsilyl)isoleucine (Isoleucine-2TMS), bis(trimethylsilyl)proline (Proline-2TMS), tris(trimethylsilyl)serine (Serine-3TMS), bis(trimethylsilyl)glutaric acid (Glutaric acid-2TMS), bis(trimethylsilyl)α-ketoglutaric acid-methyloxime (α-Ketoglutaric acid-methyloxime-2TMS), tris(trimethylsilyl)creatinine (Creatinine-3TMS), tris(trimethylsilyl)glutamic acid (Glutamic acid-3TMS), Examples of such derivatives include tris(trimethylsilyl)asparagine (Asparagine-3TMS), pentakis(trimethylsilyl)fructose-methyloxime (Fructose-methyloxime-5TMS), tetrakis(trimethylsilyl)uric acid (Uric acid-4TMS), and bis(trimethylsilyl)tryptophan (Tryptophan-2TMS). When a specific compound is derivatized, multiple derivatives (e.g., Glycine-2TMS and Glycine-3TMS) may be obtained for a single specific compound (e.g., Glycine, described below). In such cases, one or more of the multiple derivatives may be selected at will. When multiple derivatives are selected, a predetermined coefficient (described below) is set for each of the multiple derivatives in the use step described below. Furthermore, the coefficient may be set by adding together the detected amounts of the multiple derivatizations. The detected amounts of the multiple derivatives and the corresponding predetermined coefficients are then substituted into the prediction discriminant. Even when a plurality of derivatives are used from one specific compound, the number of selected specific compounds is treated as one type.
[0024] During pretreatment, it is preferable to mix a stable isotope and / or an internal standard of a specific compound with the sample. By mixing a stable isotope, the absolute amount of a specific compound contained in a body fluid such as blood can be measured. Furthermore, by mixing an internal standard, the accuracy of quantification by mass spectrometry can be improved. Examples of stable isotopes include compounds in which one or more carbon, hydrogen, nitrogen, or oxygen atoms in the molecule are substituted with stable carbon isotopes (C, C), stable hydrogen isotopes (H, H, D), stable nitrogen isotopes (N, N), or stable oxygen isotopes (O, O, O). The internal standard may be any substance that is not naturally contained in body fluids, such as 2-isopropylmalic acid, ribitol, or tropic acid.
[0025] The pretreated sample is detected by the above-mentioned detection method. The detection method conditions may be appropriately carried out according to the conditions recommended for the device used in the detection method (e.g., GC / MS device, LC / MS device).
[0026] This allows the detection amount of each specific compound contained in the sample to be obtained. The detection amount is determined appropriately depending on the detection method and detection device, and is output, for example, as concentration; peak area / peak intensity of a mass spectrum or mass chromatogram; light intensity, etc. In this case, the detection amount may be converted. For example, when the detection amount of a specific compound is output as a peak area of a mass spectrum, the peak area may be converted to concentration. That is, the "detection amount" in the first embodiment includes not only the detection amount directly output from the detection device, but also the amount obtained by converting the detection amount into another parameter. Examples of conversion include known methods such as the internal standard method and the absolute calibration curve method, and the conversion may be performed using any means, such as an analysis function attached to the detection device, a separate analysis device, or manually. In the first embodiment, it is preferable to use concentration as the detection amount, and it is particularly preferable to use the concentration (μg) of the specific compound present in 1 mL of serum.
[0027] (Using step) In this step, at least all of the 14 types of detected amounts obtained in the detecting step are used. Specifically, all of the 14 types of detected amounts of a specific compound are used, and based on the results of the use, the risk of a subject developing NAFLD in the future is evaluated. Through this use, the level of risk of developing NAFLD for the subject is evaluated.
[0028] For example, the amounts of all 14 specific compounds detected in a sample from a subject are used in a predetermined formula, specifically, substituted into a prediction discriminant, and the obtained results are used to evaluate whether the subject is likely to develop NAFLD in the future.
[0029] The prediction discriminant includes a sum (specifically, the second term on the right side of Equation (1) described later) of values obtained by multiplying each of the detected amounts of 14 specific compounds by a predetermined coefficient for each specific compound. That is, each detected amount of a compound (14 types) is multiplied by a coefficient specific to each compound that is predetermined for each compound. As a result, 14 values are obtained for each compound, and these values are summed to derive a sum, which is then substituted into the prediction discriminant.
[0030] Examples of such prediction discriminants include the following equations (1) and (2).
[0031]
[0032] The result of the prediction discriminant, i.e., the hazard ratio, is used as a criterion for determining whether or not a subject will develop NAFLD in the future (e.g., within 1 to 3 years). For example, if the hazard ratio is 4 or greater, the subject is determined to have a high risk of developing NAFLD; if the hazard ratio is 1 or greater but less than 4, the subject is determined to have a medium risk of developing NAFLD; and if the hazard ratio is less than 1, the subject is determined to have a low likelihood of developing NAFLD.
[0033] The constant K and the predetermined coefficients (14 types of coefficients) of each compound can be obtained, for example, by previously acquiring data from a large number of samples from healthy individuals and samples from NAFLD patients, and calculating and verifying this data using a statistical machine learning method (such as LASSO). In the first embodiment, the inventors have already collected a large amount of follow-up data on NAFLD disease in healthy individuals over the past three years, and the results are shown in Tables 2 to 8 in the Examples section described below. These constants K and the coefficients of each compound can be used.
[0034] In addition to using the hazard ratio calculated by the above formulas (1) and (2), for example, (i) a value using the detected amount of a specific compound detected in a subject's sample (the subject's value) is compared with a value using the detected amount of a specific compound detected in samples from individuals who remained healthy for a predetermined period after sample collection, or individuals who were healthy at the time of sample collection but developed NAFLD within the predetermined period (the value for the normal group or the value for the NAFLD prevalence group), and (ii) the risk of future NAFLD onset may be determined to be high or low based on whether the subject's value is higher or lower than the value for the normal group or the value for the NAFLD prevalence group. Specifically, (i) the value obtained by substituting the detected amount of the subject into the second term on the right side of the above formula (1) is compared with the result obtained by substituting the detected amount of the normal group or the NAFLD prevalence group into the second term on the right side of the above formula (1). And (ii) if the subject's value is equal to or higher (or lower) than the value of the NAFLD pre-group (threshold for NAFLD onset), the subject is judged to have a high risk of developing NAFLD in the future, and if the subject's value is equal to or lower (or higher) than the value of the normal group (threshold for normal), the subject is judged to have a low risk of developing NAFLD in the future. Part or all of this using step may be processed by a computer.
[0035] The evaluation method of the first embodiment can predict whether a subject will develop NAFLD in the future. As a result, the subject's risk of developing NAFLD is assessed. Therefore, for example, if a medical professional presents the results of this evaluation method to a physician, the physician can use the results to help guide the patient in developing a preventive NAFLD treatment plan. Specifically, a treatment step can be performed after this evaluation method, particularly after the use step. Examples of treatment steps include known methods for treating NAFLD, such as dietary therapy, exercise therapy, drug therapy, and surgical therapy. Dietary therapy, exercise therapy, and surgical therapy aimed at weight loss are effective, and medications used in drug therapy include, for example, antioxidants and antidiabetic drugs. These therapies are applied in appropriate combinations depending on the subject's condition.
[0036] 2. Other Embodiments In the first embodiment, the detection results of 14 specific compounds are used, but the present invention may include the detection amounts of 31 specific compounds, and may also include the detection amounts of other compounds. In other words, the detection amounts of 15 or more compounds may be used. Examples are shown below.
[0037] 2-1. 31 Types of Specific Compounds In this embodiment, in addition to 14 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan, pyruvic acid, 2-aminobutyric acid, succinic acid, threonine, decanoic acid, methionine, phenylalanine, xylose, arabinose, α-aminoadipic acid, lysine, 1-hexadecanol, tyrosine, myo-inositol, uridine, glycine, and leucine are used as biomarkers for assessing the risk of developing NAFLD. Specifically, 31 compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, pyruvic acid, 2-aminobutyric acid, succinic acid, threonine, decanoic acid, methionine, phenylalanine, xylose, arabinose, α-aminoadipic acid, lysine, 1-hexadecanol, tyrosine, myo-inositol, uridine, glycine, and leucine are used as biomarkers for assessing the risk of developing NAFLD. These 31 compounds are collectively referred to as specific compounds.
[0038] The present embodiment is similar to the above embodiment except that these 31 compounds are used as biomarkers. That is, the evaluation method of this implementation step includes an acquisition step, a detection step, and a use step, as described above in the first embodiment. This embodiment also achieves the same effects as the first embodiment.
[0039] In the detection step, the trimethylsilylated derivatives of the 31 specific compounds include, in addition to the trimethylsilylated derivatives of the above 14 specific compounds, for example, trimethylsilylpyruvic acid-methyloxime (Pyruvic acid-methyloxime-TMS), bis(trimethylsilyl)2-aminobutyric acid (2-Aminobutyric acid-2TMS), bis(trimethylsilyl)succinic acid (Succinic acid-2TMS), tris(trimethylsilyl)threonine (Threonine-3TMS), trimethylsilyldecanoic acid (Decanoic acid-TMS), bis(trimethylsilyl)methionine (Methionine-2TMS), bis(trimethylsilyl)phenylalanine (Phenylalanine-2TMS), tetrakis(trimethylsilyl)xylose-methyloxime (Xylose-methyloxime-4TMS), Tetrakis(trimethylsilyl)arabinose-methyloxime (Arabinose-methyloxime-4TMS), tris(trimethylsilyl)α-aminoadipic acid (Aminoadipic acid-3TMS), tetrakis(trimethylsilyl)lysine (Lysine-4TMS), trimethylsilyl 1-hexadecanol (1-Hexadecanol-TMS), tris(trimethylsilyl)tyrosine (Tyrosine-3TMS), hexakis(trimethylsilyl)myo-inositol (myo-Inositol-6TMS), tetrakis(trimethylsilyl)uridine (Uridine-4TMS), bis(trimethylsilyl)glycine (Glycine-2TMS) and / or tris(trimethylsilyl)glycine (Glycine-3TMS), bis(trimethylsilyl)leucine (Leucine-2TMS), In the using step, at least 31 types of detected amounts are used. Specifically, the detected amounts (concentrations, etc.) of at least 31 types of specific compounds (or derivatives thereof) are multiplied by predetermined coefficients for the specific compounds, and the sum of the values obtained is used in the prediction discriminant.
[0040] 2-2. 21 Types of Specific Compounds In this embodiment, in addition to 14 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan, 3-hydroxybutyric acid, leucine, glycine, methionine, glucose, tyrosine, and myo-inositol are used as biomarkers for assessing the risk of developing NAFLD. That is, 21 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, 3-hydroxybutyric acid, leucine, glycine, methionine, glucose, tyrosine, and myo-inositol are used as biomarkers for assessing the risk of developing NAFLD. These 21 types of compounds are collectively referred to as specific compounds.
[0041] The present embodiment is similar to the above embodiment except that these 21 compounds are used as biomarkers. That is, the evaluation method of this implementation step includes an acquisition step, a detection step, and a use step, as described above in the first embodiment. This embodiment also achieves the same effects as the first embodiment.
[0042] In the detection step, examples of the trimethylsilylated derivatives of the 21 specific compounds include, in addition to the trimethylsilylated derivatives of the above-mentioned 14 specific compounds, bis(trimethylsilyl)3-hydroxybutyric acid (3-Hydroxybutyric acid-2TMS), bis(trimethylsilyl)leucine (Leucine-2TMS), bis(trimethylsilyl)glycine (Glycine-2TMS) and / or tris(trimethylsilyl)glycine (Glycine-3TMS), bis(trimethylsilyl)methionine (Methionine-2TMS), pentakis(trimethylsilyl)glucose-methyloxime (Glucose-methyloxime-5TMS), tris(trimethylsilyl)tyrosine (Tyrosine-3TMS), and hexakis(trimethylsilyl)myo-inositol (myo-Inositol-6TMS). In the using step, at least 21 types of detected amounts are used. Specifically, the detected amounts of the at least 21 types of specific compounds are multiplied by a predetermined coefficient for each specific compound, and the sum obtained by multiplying the values is used in the prediction discriminant.
[0043] 2-3. 15 Types of Specific Compounds In this embodiment, in addition to 14 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan, glycine is used as a biomarker for assessing the risk of developing NAFLD. That is, 15 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and glycine are used as biomarkers for assessing the risk of developing NAFLD. These 15 types of compounds are collectively referred to as specific compounds.
[0044] The present embodiment is similar to the above embodiment except that these 15 compounds are used as biomarkers. That is, the evaluation method of this implementation step includes an acquisition step, a detection step, and a use step, as described above in the first embodiment. This embodiment also achieves the same adoption effects as the first embodiment.
[0045] In the detection step, the trimethylsilylated derivatives of the 15 specific compounds include, in addition to the trimethylsilylated derivatives of the 14 specific compounds, for example, bis(trimethylsilyl)glycine (Glycine-2TMS) and / or tris(trimethylsilyl)glycine (Glycine-3TMS). In the use step, the amounts of at least 15 specific compounds are used. Specifically, the amounts of the at least 15 specific compounds are multiplied by a predetermined coefficient for each specific compound, and the resulting sum is used in the prediction discriminant.
[0046] 3. Aspects It will be appreciated by those skilled in the art that the exemplary embodiments described above are examples of the following aspects.
[0047] (Item 1) A method for assessing the risk of developing non-alcoholic fatty liver disease according to one embodiment may include a detection step of detecting 14 compounds in the sample, the compounds being lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan, and an application step of using all of the detected amounts of the 14 compounds obtained in the detection step. This assessment method makes it possible to predict whether a subject will develop NAFLD in the future.
[0048] (Item 2) In the evaluation method according to item 1, glycine may be detected in addition to the 14 compounds, and all of the 15 detected amounts obtained in the detection step may be used in the using step. This evaluation method makes it possible to more reliably predict whether or not a subject will suffer from NAFLD.
[0049] (Item 3) In the evaluation method according to item 1, in addition to the 14 compounds, 3-hydroxybutyric acid, leucine, glycine, methionine, glucose, tyrosine, and myo-inositol may be detected, and the amounts of all 21 compounds detected by the detection step may be used in the using step. This evaluation method makes it possible to more reliably predict whether or not a subject will suffer from NAFLD.
[0050] (Item 4) In the evaluation method according to item 1, in addition to the 14 compounds, pyruvic acid, 2-aminobutyric acid, succinic acid, threonine, decanoic acid, methionine, phenylalanine, xylose, arabinose, α-aminoadipic acid, lysine, 1-hexadecanol, tyrosine, myo-inositol, uridine, glycine, and leucine may be detected, and the amounts of all 31 compounds detected by the detection step may be used in the using step. This evaluation method makes it possible to more reliably predict whether or not a subject will suffer from NAFLD.
[0051] (5) In the evaluation method according to any one of items 1 to 4, the using step may include at least summing values obtained by multiplying the detected amounts of the 14 types of compounds obtained in the detecting step by a predetermined coefficient for each of the 14 types of compounds. This evaluation method makes it possible to more reliably predict whether a subject will develop NAFLD in the future.
[0052] (Item 6) In the evaluation method according to any one of Items 1 to 5, the detection step may include obtaining concentrations of the 14 types of compounds or derivatives thereof. This evaluation method makes it possible to more reliably predict whether a subject will develop NAFLD in the future.
[0053] (7) In the evaluation method according to the above item 6, the derivative may be one that has been derivatized by silylation, acylation, esterification, or alkylation. This evaluation method allows for the sensitive detection of the derivative, thereby enabling more accurate prediction of whether or not a patient is affected by NAFLD.
[0054] (Item 8) In the evaluation method according to any one of Items 1 to 7, the detection step may be performed by gas chromatography, liquid chromatography, mass spectrometry, gas chromatography / mass spectrometry, liquid chromatography / mass spectrometry, nuclear magnetic resonance spectroscopy, or an immunological detection method. This evaluation method uses a detection method with high sensitivity, making it possible to more accurately predict whether or not a subject will suffer from NAFLD.
[0055] (Item 9) In the evaluation method according to any one of Items 1 to 8, the body fluid may be blood. According to this evaluation method, measurement samples are easily available and the method is minimally invasive to the subject, thereby reducing the burden of diagnosis on the subject.
[0056] (Item 10) A biomarker for assessing the risk of developing non-alcoholic fatty liver disease according to one embodiment may include 14 compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan. This biomarker can be used to predict whether a subject will develop NAFLD in the future.
[0057] (Item 11) The biomarker for assessing the risk of developing non-alcoholic fatty liver disease according to Item 10 may contain 15 compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, and glycine. This biomarker can more reliably predict whether or not a patient will suffer from NAFLD.
[0058] (Item 12) The biomarker for assessing the risk of developing non-alcoholic fatty liver disease according to Item 10 may contain 21 compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, 3-hydroxybutyric acid, leucine, glycine, methionine, glucose, tyrosine, and myo-inositol. This biomarker makes it possible to more reliably predict whether or not a subject will suffer from NAFLD.
[0059] (Item 13) The biomarker for assessing the risk of developing non-alcoholic fatty liver disease described in Item 10 may contain 31 compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, pyruvic acid, 2-aminobutyric acid, succinic acid, threonine, decanoic acid, methionine, phenylalanine, xylose, arabinose, α-aminoadipic acid, lysine, 1-hexadecanol, tyrosine, myo-inositol, uridine, glycine, and leucine. This biomarker enables more reliable prediction of whether or not a subject will suffer from NAFLD.
[0060] <Examples> In the following examples, GC / MS was performed using serum obtained from patients who had been diagnosed with NAFLD by abdominal ultrasound findings within the past three years (NAFLD pre-group) and serum obtained from patients who had been healthy for the past three years (normal group), and the results of the analysis conducted to search for components in the serum with different concentrations between the NAFLD pre-group and the normal group are described.
[0061] (Subjects) Serum samples were used from 4,495 randomly selected Japanese people who visited the hospital for a health checkup between October 2015 and September 2016 and met the inclusion criteria. The inclusion criteria were those who did not fall into any of the following categories (1) to (5): (1) Those who declined to participate in the study. (2) Those with an alcohol intake of 30 g or more per day (equivalent to ethanol) for men and 20 g or more per day (equivalent to ethanol) for women. (3) Those with a history of current treatment for liver disease. (4) Those with a history of current treatment for at least one of the following: diabetes, dyslipidemia, or hyperuricemia. (5) Those with a history of current treatment for malignant disease.
[0062] All individuals who met the above inclusion criteria had abdominal ultrasound findings obtained during a medical checkup, and the clinical information was compared with the results of serum analysis with the consent of the hospital's research ethics committee.
[0063] (Pretreatment) After blood was collected from the subject, serum was extracted by centrifugation and frozen at -80°C within 6 hours of collection. The frozen serum was thawed by leaving it at 25°C for 5 minutes. The thawed serum was centrifuged, and the supernatant was collected into a tube containing a specified amount of 40 stable isotopes (Table 1 lists only the stable isotopes corresponding to 31 of the 40 metabolites being measured). The collected serum was mixed with 250 μL of a chloroform mixed solvent (methanol / water / chloroform = 2.5:1:1) and 6 μL of an internal standard solution (2-isopropylmalic acid; 0.1 mg / mL), shaken, and centrifuged. Then, 140 μL of water was added, shaken, and centrifuged to obtain a sample containing the internal standard and stable isotope. 180 μL of this sample was concentrated using a centrifugal evaporator at room temperature for 60 minutes, left to stand at −80° C. for 30 minutes to freeze, and then dried overnight using a freeze dryer.
[0064]
[0065] (Derivatization) The dried sample was mixed with 80 μL of a pyridine solution containing methoxyamine hydrochloride (methoxyamine hydrochloride; 20 mg / mL) and 40 μL of N-methyl-N-trimethylsilyltrifluoroacetamide, followed by shaking and centrifugation. 50 μL of the resulting supernatant was placed in the autosampler of the GC / MS.
[0066] (GC / MS Measurement) Gas chromatography mass spectrometry was carried out on the sample under the following conditions. <Gas chromatography conditions> System: GCMS-TQ8040 (Shimadzu Corporation) Column oven temperature: 80°C Injection temperature: 280°C Injection mode: Split introduction Carrier gas: Helium Carrier gas flow rate: 39 cm / sec Separation column: DB-5 (Agilent Technologies) Stationary phase: (5%-phenyl)-methylpolysiloxane (non-polar) Column length: 30.0 m, column inner diameter: 0.25 mm, column film thickness: 1.00 μm Column temperature program: 80°C (0 min) / 80°C (2.5 min) / 280°C (18.5 min) / 280°C (23.0 min) <Mass spectrometry conditions> System: GCMS-TQ8040 (Shimadzu Corporation) Ion source temperature: 200°C Interface temperature: 250°C Detector voltage: 0.2 kV Measurement mode: MRM mode Scanning range: m / z 82-500
[0067] (Calculation of detection amount) A mass spectrum at each retention time was output from the detection intensity obtained by scanning m / z at each retention time. Based on the mass spectrum data of a serum sample obtained in the past, metabolites (40 types) corresponding to each peak in the mass spectrum and the stable isotopes corresponding to those metabolites were identified. The detection intensity corresponding to each metabolite was standardized using the detection intensity of the stable isotope corresponding to each metabolite, and the concentration (unit: μg / mL) in the sample was calculated as the detection amount.
[0068] (Data Analysis) Based on clinical diagnostic information and the detected amounts obtained by GC / MS, combinations of metabolites that can distinguish between the normal and disease groups were investigated using LASSO, a machine learning method. Specifically, before running LASSO, subjects were divided into two groups, a training set and a test set, and a prediction discriminant was developed using the training set and validated using the test set. In running LASSO, logistic regression with 10-fold cross-validation was applied.
[0069] As a result, 31 compounds were selected as discriminable metabolites, as shown in Table 2 below. Their regression coefficients were calculated, and prediction discriminants were derived as shown in the following formulas (1) and (2). The relationship between the hazard ratio and the incidence rate was calculated as shown in Table 3. Regarding the prediction discriminant, the prediction score (formula (1) below) is calculated by adding a predetermined constant (the first term on the right side) and the sum of the detected amounts of each compound multiplied by each coefficient (the second term on the right side). This prediction score is a logarithmic hazard ratio, and the hazard ratio (the hazard ratio relative to the median hazard in the general population for developing NAFLD) is derived by calculating 1e [prediction score]. This hazard ratio is the hazard ratio for each individual when the hazard in the general population is used as the reference (hazard ratio = 1), and a higher value indicates a higher risk of developing NAFLD. Specific criteria are shown in Table 3.
[0070]
[0071]
[0072] In Table 2, TMS represents a trimethylsilylated derivative. In Equation 1, the second term on the right side is the sum of 31 compounds, the constant K and the coefficient of each compound are as shown in Table 2, and the detection amount of each compound was the concentration (μg) of the specific compound present in 1 mL of serum.
[0073]
[0074] A time-dependent receiver operating characteristic (ROC) analysis was performed on the predictive discriminant, and the results are shown in Figure 1. For quantitative evaluation, the AUC was calculated, yielding favorable values of 0.80 and 0.76 for the training and test sets, respectively. This demonstrates that the evaluation method of the present embodiment has good discrimination performance. Furthermore, since it is based on a large amount of data from a normal group and a pre-NAFLD group (4,495 individuals), it is highly reliable.
[0075] In addition, as a separate cohort, 862 sera samples were randomly selected from Japanese patients undergoing a comprehensive medical checkup at a different time point. These samples met the above inclusion criteria. ROC analysis was also performed on this separate cohort, and the results are shown in Figure 2. The AUC was 0.77.
[0076] Example 2: Six metabolites with unstable elements (leucine-TMS, decanoic acid-TMS, 1-hexadecanol-TMS, uridine-4TMS, 2-aminoadipic acid-3TMS, histidine-3TMS) were excluded from the 40 metabolites to enhance analytical stability. The values of 34 metabolites (specific compounds) were subjected to the LASSO method in the same manner as in Example 1 (cohort of 4,495 individuals). As a result, 21 metabolites were selected as distinguishable metabolites, as shown in Table 4 below. Their regression coefficients were calculated, and the relationship between the hazard ratio and the incidence rate was calculated, as shown in Table 5 below.
[0077]
[0078]
[0079] Using the above 21 metabolites, ROC analysis was performed in the same manner as in Example 1, and the results are shown in Figure 3. The AUC in this case was a good value of 0.79 for both the training set and the test set.
[0080] Example 3: Six metabolites with unstable elements (leucine-TMS, decanoic acid-TMS, 1-hexadecanol-TMS, uridine-4TMS, 2-aminoadipic acid-3TMS, histidine-3TMS) were excluded from the 40 metabolites, and the values of 15 metabolites (specific compounds) were subjected to the LASSO method in the same manner as in Example 1 (cohort of 4,495 individuals), except that a mode was run to minimize the number of metabolites. As a result, 15 metabolites were selected as distinguishable metabolites, as shown in Table 6 below, and their regression coefficients were calculated. Furthermore, the relationship between the hazard ratio and the incidence rate was calculated, as shown in Table 7 below.
[0081]
[0082]
[0083] Using the above 15 metabolites, ROC analysis was performed in the same manner as in Example 1, and the results are shown in Figure 4. The AUC in this case was a good value of 0.78 for both the training set and the test set.
[0084] Example 4 Fourteen compounds common to Examples 1 to 3 were selected as distinguishable compounds (see Table 8 below). In addition, the relationship between the hazard ratio and the incidence rate was calculated, as shown in Table 9 below.
[0085]
[0086]
[0087] Using the above 14 specific compounds, ROC analysis was performed in the same manner as in Example 1, and the results are shown in Figure 5. The AUCs were good values of 0.77 and 0.78 for the training set and test set, respectively.
Claims
1. A method for assessing the risk of developing non-alcoholic fatty liver disease, comprising: an obtaining step of obtaining a sample derived from the body fluid of a subject; a detecting step of detecting 14 types of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan in the sample; and an using step of using all of the 14 types of compounds detected in the detecting step.
2. The method for assessing the risk of developing the disease described in claim 1, wherein in the detection step, glycine is detected in addition to the 14 types of compounds, and in the use step, all of the detected amounts of the 15 types obtained in the detection step are used.
3. The method for assessing the risk of developing the disease according to claim 1, wherein in the detection step, 3-hydroxybutyric acid, leucine, glycine, methionine, glucose, tyrosine, and myo-inositol are detected in addition to the 14 types of compounds, and in the use step, all of the detected amounts of the 21 types obtained in the detection step are used.
4. The method for assessing the risk of onset according to claim 1, wherein in the detection step, in addition to the 14 types of compounds, pyruvic acid, 2-aminobutyric acid, succinic acid, threonine, decanoic acid, methionine, phenylalanine, xylose, arabinose, α-aminoadipic acid, lysine, 1-hexadecanol, tyrosine, myo-inositol, uridine, glycine, and leucine are detected, and in the use step, all of the detected amounts of the 31 types obtained in the detection step are used.
5. A method for assessing the risk of onset as described in claim 1, wherein in the using step, the values obtained by multiplying each of the detected amounts of the 14 types of compounds by a predetermined coefficient for each of the 14 types of compounds are at least summed.
6. The method for assessing the risk of developing the disease according to claim 1, wherein the detection step obtains the concentrations of the 14 types of compounds or their derivatives.
7. The method for assessing the risk of developing a disease according to claim 6, wherein the derivative is derivatized by silylation, acylation, esterification or alkylation.
8. The method for assessing the risk of developing the disease described in claim 1, wherein the detection process is carried out by gas chromatography, liquid chromatography, mass spectrometry, gas chromatography / mass spectrometry, liquid chromatography / mass spectrometry, nuclear magnetic resonance spectroscopy, or an immunological detection method.
9. The method for assessing the risk of disease according to claim 1, wherein the body fluid is blood.
10. A biomarker for assessing the risk of developing non-alcoholic fatty liver disease, comprising 14 compounds consisting of lactate, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid and tryptophan.
11. The biomarker of claim 10, comprising 15 compounds consisting of lactate, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, and glycine.
12. The biomarker of claim 10, comprising 21 compounds consisting of lactate, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, 3-hydroxybutyrate, leucine, glycine, methionine, glucose, tyrosine, and myo-inositol.
13. The biomarker of claim 10, comprising 31 compounds consisting of lactate, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, tryptophan, pyruvic acid, 2-aminobutyric acid, succinic acid, threonine, decanoic acid, methionine, phenylalanine, xylose, arabinose, α-aminoadipic acid, lysine, 1-hexadecanol, tyrosine, myo-inositol, uridine, glycine, and leucine.
Citation Information
Patent Citations
Trimethylamine-containing compounds for disease diagnosis and prediction
JP2012528340A
Method of detecting nafld or NASH, or predicting risk thereof, diagnostic kit for detecting nafld or NASH, and method and diagnostic kit for determining progression of liver fibrosis in subject
JP2020034561A
Risk assessment method for non-alcoholic liver disease using single nucleotide polymorphism
JP2020120625A
Composition for predicting or diagnosing liver disease and method for predicting or diagnosing liver disease using the same
JP2020528138A
Method for diagnosing liver disease
JP2016065873A
